Status:

RECRUITING

A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy

Lead Sponsor:

Epicrispr Biotechnologies, Inc.

Conditions:

Facioscapulohumeral Muscular Dystrophy

Eligibility:

All Genders

18-75 years

Phase:

PHASE1

PHASE2

Brief Summary

The goal of this clinical trial is to learn how safe and tolerable EPI-321 is and whether there may be early signs it is working in male or female adult (18 to 75 years) participants with facioscapulo...

Detailed Description

EPI-321 is an investigational drug product comprising a recombinant adeno-associated viral vector, serotype rh74 (AAVrh74), for the delivery of genetic material encoding an epigenetic editor designed ...

Eligibility Criteria

Inclusion

  • Able and willing to provide informed consent
  • Male or female 18 to 75 years of age
  • Clinical diagnosis of FSHD with genetic Type 1
  • FSHD Ricci clinical severity score 2 to 4 (on 5-point scale)
  • Has adequate liver function
  • Has adequate kidney function

Exclusion

  • Has an anti-AAVrh74 total binding antibody titer \> 1:400
  • Requires a walker or wheelchair for ambulation
  • Pregnant and/or breastfeeding at baseline or is planning to become pregnant during the first 12 months following EPI-321 administration
  • Has FSHD Type 2
  • Has a concurrent or past medical conditions could jeopardize the safety of the participant

Key Trial Info

Start Date :

May 8 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 30 2032

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT06907875

Start Date

May 8 2025

End Date

April 30 2032

Last Update

December 16 2025

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

David Geffen School of Medicine at University of California, Los Angeles

Los Angeles, California, United States, 90095

2

Rare Disease Research

Atlanta, Georgia, United States, 303329

3

University of Massachusetts Chan Medical School

Worcester, Massachusetts, United States, 01605

4

Utah Program for Inherited Neuromuscular Disorders - University of Utah

Salt Lake City, Utah, United States, 84112